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Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The high risk of recurrence following
surgical resection provides the rationale for adjuvant therapy. However, only a subset of patients benefit from adjuvant
therapy. Identification of molecular markers to predict treatment outcome is therefore warranted. The aim of the present
study was to evaluate whether expression of novel candidate biomarkers, including microRNAs, can predict clinical outcome
in PDAC patients treated with adjuvant therapy.
Methodology/Principal Findings: Formalin-fixed paraffin embedded specimens from a cohort of 82 resected Korean PDAC
cases were analyzed for protein expression by immunohistochemistry and for microRNA expression using quantitative Real-
Time PCR. Cox proportional hazards model analysis in the subgroup of patients treated with adjuvant therapy (N = 52)
showed that lower than median miR-21 expression was associated with a significantly lower hazard ratio (HR) for death
(HR= 0.316; 95%CI = 0.166–0.600; P = 0.0004) and recurrence (HR = 0.521; 95%CI = 0.280–0.967; P = 0.04). MiR-21 expression
status emerged as the single most predictive biomarker for treatment outcome among all 27 biological and 9
clinicopathological factors evaluated. No significant association was detected in patients not treated with adjuvant therapy.
In an independent validation cohort of 45 frozen PDAC tissues from Italian cases, all treated with adjuvant therapy, lower
than median miR-21 expression was confirmed to be correlated with longer overall as well as disease-free survival.
Furthermore, transfection with anti-miR-21 enhanced the chemosensitivity of PDAC cells.
Conclusions Significance: Low miR-21 expression was associated with benefit from adjuvant treatment in two independent
cohorts of PDAC cases, and anti-miR-21 increased anticancer drug activity in vitro. These data provide evidence that miR-21
may allow stratification for adjuvant therapy, and represents a new potential target for therapy in PDAC.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer related
death and over the last decades little improvement in survival has
been observed despite extensive research efforts [1]. About 95% of
exocrine pancreatic cancers are pancreatic ductal adenocarcino-
mas (PDAC), of which incidence has risen steadily over the last
decades [1,2]. Surgery is feasible in 15–20% of patients but, even
after complete resection, prognosis remains dismal, with a 5-year
survival rate lagging at 10–20% [3].
Pancreatic cancer is notoriously resistant to chemotherapy and
radiotherapy. Adjuvant treatment is modestly effective and can
have substantial toxicities. Therefore, the role of adjuvant therapy
in resectable pancreatic cancer is still unclear, though generally
thought to benefit a subset of patients [4,5]. Being able to identify
this subset would be a great advance in the management of this
disease as it would allow patient stratification for adjuvant
treatment [6]. Therefore, predictive markers of sensitivity to
adjuvant therapy as well as new therapeutic targets are urgently
needed in this disease [7,8].
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Altered expression of several factors has been associated with
PDAC aggressive behaviour and prognosis. For example, among
all cancers, PDAC has the highest frequency of K-Ras mutations,
which has led to speculation regarding its application as a
diagnostic as well as a prognostic marker [7]. The protein product
of K-Ras is a GTP-binding protein mediating a number of critical
cellular functions, including proliferation, cell survival and
motility. However, most of the evidence, so far, suggests that K-
ras mutations are not significantly associated with survival in
pancreatic cancer patients [9,10]. Other studies suggested the
prognostic significance of altered expression of proteins involved in
the Ras signaling pathway, such as Akt. Nevertheless, phosphor-
ylated Akt expression levels were associated with both shorter and
longer survival in resectable PDAC patients [11,12]. Other
markers reported as independent predictors of PDAC prognosis
include p16, matrix metalloproteinase 7 (MMP-7) and vascular
endothelial growth factor (VEGF) expression [13]. Still, many
biological aspects governing this disease are still poorly understood
and no single marker has been shown to accurately predict clinical
outcome.
In recent years, it has become clear that protein expression can
also be regulated by microRNAs (miRNAs) [14]. MicroRNAs are
a class of small non-coding RNAs that interact with the mRNAs of
coding genes to direct their posttranscriptional repression [15].
MicroRNA have been shown to be involved in oncogenesis and
tumor growth, and also to play a major role in chemoresistance
[16–19].
Furthermore, the expression of microRNAs is tissue specific,
and certain cancer histotypes can be classified based on
microRNA expression profiles [20,21]. In pancreatic cancer,
several miRNAs have been reported to be aberrantly expressed,
including microRNAs with key roles in cancer, such as
‘‘onco(genic)-miRs’’, miR-21 and miR-155, and ‘‘tumor suppres-
sor miRs’’, miR-29b and the miR-34 and Let-7 families [22–29].
Preclinical studies in PDAC cells showed that exogenous miR-34
overexpression was associated with reconstitution of p53-depen-
dent tumor suppressor function in p53-deficient cells as well as
inhibition of pancreatic cancer stem cell self-renewal [30]. Up-
regulation of Let-7 is associated with reversal of epithelial to
mesenchymal transition (EMT) in gemcitabine-resistant cells [31].
MicroRNA-29b can target de novo DNA methyltransferase 3A
and 3B (DNMT3A and DNMT3B) and lead to global hypo-
methylation and overexpression of various tumor suppressor
genes, including p16 [32]. MicroRNA-21 expression is associated
with increased proliferation, invasive properties, and gemcitabine
chemoresistance and a previous study showed that high miR-21
expression, as determined by in situ hybridization, was predictive
of shorter survival in PDAC node-negative patients [28,33].
MicroRNA-155 is involved in the repression of Tumor protein 53-
induced nuclear protein 1, which is a proapoptotic stress-induced p53
target gene and a negative prognostic effect of high miR-155
expression was observed in a cohort of PDAC cases including
patients with advanced disease and/or local R2-resection [34,35].
The aim of the present study was to evaluate potential biological
markers to predict outcome from adjuvant chemotherapy.
Therefore, we have performed an integrative analysis of the
expression of miR-21, miR-29b, miR-34a/b/c, miR-155 and let-
7a-2 in a cohort of PDAC patients, with known pathological and
treatment characteristics. Additionally, we have investigated
expression of 20 known potential protein markers and targets for
therapy, involved in PDAC progression and prognosis (See Table
S1 for a complete overview of the 27 biological and 9
clinicopathological factors used in the study) [6,13]. Since miR-
21 expression status emerged as the single most predictive
biomarker for treatment outcome from all factors evaluated in
adjuvant-treated patients, further analysis of miR-21 expression
was performed in a second cohort of 45 patients, all treated with
adjuvant therapy. This independent set confirmed the significant
association of miR-21 expression status with both survival and
disease-free survival. In addition, the association of low miR-21
expression with benefit from adjuvant treatment was supported by
in vitro data showing the increased chemosensitivity of PDAC cells
after transfection with anti-miR-21.
Methods
Participants, study centers, treatment details
Two hundred forty five patients who underwent pancreatic
cancer resection with the final diagnosis of pancreatic cancer were
retrospectively reviewed using electronic medical records during
the period 1999–2007 at Seoul National University Hospital and
Seoul National University Bundang Hospital. Among them,
eighty-two patients had completely resected (R0) pancreatic
adenocarcinoma and were included in the study. Pathologic
tumor stage was determined according to the American Joint
Committee on Cancer (AJCC) Cancer Staging, 6th edition [36].
Briefly, in pathologic T1-2 stages (pT1-2) tumor involvement is
limited to the pancreas, tumor size being less or greater than 2 cm
for stages pT1 and pT2, respectively. Pathologic T3 (pT3) stage
tumors extend beyond the pancreas, without involvement of the
celiac axis or superior mesenteric artery, whilst pT4 tumors are
characterized by involvement of the celiac axis or the superior
mesenteric artery. As for the lymph nodal stage, pathologic nodal
stage 1 (pN1) indicates regional lymph node metastasis. Finally,
M1 indicates presence of distant metastases. Disease stages I, IIA,
IIB, III and IV indicate ‘‘pT1-2 pN0 M0’’, ‘‘pT3 N0 M0’’, ‘‘pT1-3
pN1 M0’’, ‘‘pT4 any N M0’’ and ‘‘any pT any pN M1’’,
respectively. Patients received adjuvant chemotherapy, combined
chemoradiotherapy (CCRT) or both (n= 52), or did not receive
treatment (n = 27). Treatment status of three patients was
unknown. Adjuvant chemotherapy and chemo-radiotherapy
consisted of combinations of gemcitabine or 5-fluorouracil (5-
FU). FFPE specimens were reviewed for diagnosis and tumor
content at Seoul National University Hospital, as well as at
National Cancer Institute, NIH, Bethesda, MD. The validation
cohort was composed of frozen specimens from 45 consecutive
pancreatic adenocarcinoma Italian patients diagnosed in the
period 2001–2004 at the Regional Referral Center for Pancreatic
Disease Treatment, University Hospital of Pisa, Pisa, Italy [37].
Adjuvant treatment consisted of gemcitabine-based combined
modality treatment. Details of adjuvant regimens are listed in
Table S2.
Ethics
Patient consent and study approval was obtained from the local
Institutional Review Boards according to the legal regulations of
the participating countries. Informed written consent was obtained
from Korean patients who were still alive at the time of the study
through the human tissue bank. The study protocol was approved
by the Institutional Review Board of the Human Clinical Research
Center. Regarding Italian patients, written consent was obtained.
The study protocol was approved by the University of Pisa Ethics
Committee.
Immunohistochemistry
The expression of 20 protein markers and targets for therapy
were studied by immunohistochemistry (IHC). As reported in
Table S1 we evaluated the expression levels of the following
miR-21 in Pancreatic Cancer
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markers: vascular endothelial growth factor (VEGF), matrix
metalloproteinase-2 (MMP2), matrix metalloproteinase-7 (MM-
P7), matrix metalloproteinase-9 (MMP9), tissue inhibitor of
metalloproteinase-3 (TIMP3), epidermal growth factor receptor
(EGFR), excision repair cross-complementation group 1 (ERCC1),
chemokine (C-X-C motif) receptor 3 (CXCR3), chemokine (C-X-
C motif) receptor 4 (CXCR4), amphiregulin, epiregulin, hepato-
cyte growth factor (HGF), neuropilin, insulin-like growth factor 1
receptor beta (IGF-1R), Ron b, c-Met, phosphorylated-c-Met (P-c-
Met), thymidylate synthase (TS), E-cadherin, and ribonucleotide
reductase subunit M1 (RRM1). Tissue microarray (TMA) sections
were constructed using core tissue biopsies (diameter 2 mm)
obtained from individual paraffin-embedded Korean pancreatic
cancer specimens. Biopsies were included in new recipient paraffin
blocks using a trephine apparatus (Superbiochips Laboratories,
Seoul, Republic of Korea). Each tissue array block contained up to
50 cores and 2 array blocks were prepared during the study.
TMA sections were deparaffinized using xylene, rehydrated in
alcohol and stained with specific antibodies as listed in Table S3. For
ERCC1, the H-score indicates staining intensity (0 to 3) multiplied by
a factor determined by the proportion of positive cells: 0 if 0% positive
cells, 0.1 if 1–9%, 0.5 if 10–49%, 1 if .50% positive cells. For all
other factors, positive staining meant a signal intensity equal or
greater than 2 and more than 20% of positive cells.
MicroRNA expression
RNA was isolated from FFPE sections using the RecoverAll
Total Nucleic Acid Isolation kit (Ambion, Austin, TX) and from
frozen tissue sections as reported previously [38]. RNA (10–
100 ng) was used for expression analysis of miR-21 (Italian cohort)
or miR-21, miR-29, miR-34a/b/c, let-7a-2, and miR-155
(Korean cohort) by quantitative Real-Time PCR (qRT-PCR)
with TaqMan-MicroRNA assays and the 7900 HT-Fast Real-
Time PCR (Applied Biosystems, Foster City, CA) using small
nuclear RNA U66 or RNU43, as the endogenous normalization
controls for the Korean and Italian specimens, respectively. All
assays were performed in triplicate and results which did not meet
methodological quality control criteria were omitted. Quantifica-
tion of relative microRNA expression was performed using the
delta Ct method. Expression was determined as high when the
expression level was equal or above the median of the cohort and
low when was below the median of the cohort.
In vitro studies
The human PDAC cells lines BxPc3, HPAF-II, HPAC, PANC-
1 and PL45 were purchased from the American Type Culture
Collection (ATCC, Manassas, VA), and were cultured in RPMI-
1640 media, supplemented with 10% FBS and 1% penicillin
(50 IU/mL) and streptomycin (50 mg/mL) (Gibco, Gaithersburg,
MD). Cells were kept at 37uC under an atmosphere of 5% CO2 in
75-cm2 tissue culture flasks (Greiner Bio-One GmbH, Frick-
enhausen, Germany) and harvested with trypsin-EDTA in their
exponentially growing phase. RNA was extracted using a Trizol-
chloroform protocol (Sigma, St. Louis, MO). RNA yields and
integrity were checked by measuring optical density at 260/
280 nm with a NanodropH spectrophotometer.
The basal expression of miR-21 was assessed by quantitative-Real-
Time PCR, as described above for PDAC tissues. Quantification of
miR-21 expression was performed using the delta Ct method,
normalizing the Ct amplification data with RNU43. Relative miR-21
expression levels were expressed in arbitrary units (a.u.).
Cell growth inhibition by 5-FU (0.1–1000 mM), and gemcitabine
(0.1–1000 nM) plus irradiation (100 cGy), was determined from three
separate experiments using the SRB (sulforhodamine-B) assay, and
was expressed as the percentage of control (vehicle-treated cells)
absorbance, corrected for absorbance, before drug addition, as
described previously [39]. For irradiation, exponentially growing cells
were plated in 100-mm tissue culture dishes (Costar), allowed to
attach for 24 hours, and irradiated by using a 6 MV photon linear
accelerator (General Electric, Buckinghamshire, UK). After irradia-
tion, cells were harvested and 104 cells/well were plated in 96-well
plates and allowed to grow for additional 48 h in drug-free medium
or treated with gemcitabine, as described previously [40]. The 50%
inhibitory concentration (IC50) of cell growth for each cell line was
determined by non-linear least squares curve fitting of the dose-
response curves (GraphPad PRISM version 5, Intuitive Software for
Science, San Diego, CA). The effect of miR-21 on cell growth and
chemosensitivity was evaluated by transfecting the cells with the
antisense oligonucleotides (anti-miR-21) purchased from Ambion-
Applied Biosystems (Assay ID, AM10206), at 30 nM final concen-
tration. Cells were plated at 200,000 cells/well in 3 ml RPMI with
10% FBS and 1% antibiotics. After 24 h cells were exposed to 9 ml
oligofectamine (Invitrogen, Paisley, UK) in serum-free medium,
mixed for 10 minutes at room temperature, followed by the addition
of 3 ml of 6.25 mM miR-21 precursor or inhibitor. Cells were also
incubated with miRNA negative controls and FAM-labeled anti-mir
(Ambion). After 24 hours the medium was removed from the wells
and replaced with RPMI with 10% FBS, without antibiotics. Then
cells were collected by trypsinization and transferred to a 96-well
plate, where they were allowed to grow for additional 48 h in drug-
free medium or treated with 5-FU, as described above. Additional
control wells were used for RNA extraction, as described above, while
the transfection efficiency with FAM-labeled anti-mir controls was
evaluated with fluorescence microscopy.
Statistical methods
Comparisons of dichotomous parameters were made between
two groups using Fisher’s exact test. A generalized version of
Fisher’s exact test was used for comparisons of age, tumor stage
and differentiation grade when divided into three categories [41].
The probability of overall survival (OS) or disease-free survival
(DFS) as a function of time were determined by the Kaplan-Meier
method, with a log-rank test used to determine the statistical
significance of the difference of Kaplan-Meier curves [42,43] For
the univariate prognostic factors analyses, cases in which patients
were ultimately grouped into two categories, determined after
preliminary evaluation of four categories using the quartiles of the
distribution of the grouping parameter, had the p-value adjusted
by multiplying the unadjusted p-value by three. This would
account for the implicit testing which resulted in a decision to
place patients into the two categories with a larger prognostic
difference between groups. A Cox proportional hazards model
analysis was performed to determine the joint association of factors
initially found to have potential association with outcome in the
univariate analyses (evaluating in this final model only those
parameters with unadjusted p,0.10 from a log-rank test) [44].
All p-values are two-tailed, and except as noted above, are
presented without adjustment for multiple comparisons.
All in vitro experiments were performed in triplicate and
repeated at least two times. Data was expressed as mean
values6SE and analyzed by Student’s t test and/or Mann
Whitney test. Statistical significance was set at p,0.05.
Results
Characteristics of the patients
Table 1 summarizes clinicopathological characteristics. In the
Korean patients, median OS and DFS were 18.1 and 9.1 months,
miR-21 in Pancreatic Cancer
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respectively. In this cohort OS was significantly longer for patients
treated with adjuvant chemotherapy and/or CCRT (n=52):
median survival was 21.3 vs. 14.7 months for patients treated vs.
not treated with adjuvant therapy (n= 27); p = 0.017. See Figure
S1 for Kaplan-Meier plots.
Expression analysis results
Expression of miR-21, miR-34a, miR-155 and let-7a was
detectable in all 82 cases, and expression of miR-29b, miR-34b,
and miR-34c in 81, 73 and 80 cases, respectively. In agreement
with previous studies showing that miR-34b and miR-34c share
the same transcription promoter [45], expression values of these
miRNAs were correlated (data not shown). IHC results were
available for neuropilin and MMP-9 in 80 cases, for amphiregulin,
HGF, EGFR and TIMP3 in 79 cases, for Ron, CXCR-3, e-
cadherin, RRM1, IGF-1R, TS, VEGF, MMP-2 and MMP-7 in 78
cases, for CXCR-4 in 77 cases, for c-Met and P-c-Met in 76 cases,
for ERCC1 in 75 cases and for epiregulin in 73 cases.
As described in the Methods section, for each protein we scored
the staining intensity and the percentage of positively stained cells.
In Figure S2, representative images of immunohistochemical
staining for P-c-Met are shown. Table 2 summarizes the results of
immunohistochemical staining for all the studied proteins.
Univariate analysis
A total of 36 clinicopathological, microRNA and protein
variables were evaluated for their association with OS or DFS in
the Korean cohort. Based on univariate analysis, a set of 10 and 12
parameters were considered for evaluation in the Cox models for
OS and DFS, respectively (see Table S4). Selected parameters
were also tested according to adjuvant treatment status (Table S4).
Additionally, for any parameter, the population was divided into 4
groups for comparison: (1) negative parameter, no adjuvant
treatment vs. (2) negative parameter, adjuvant treatment vs. (3)
positive parameter, no adjuvant treatment vs. (4) positive
parameter, adjuvant treatment. Table S4 only lists combinations
with an associated p-value ,0.10. Notably, a strong interaction of
miR-21 expression status and adjuvant treatment status for OS
and DFS was demonstrated. Low miR-21 expression was
associated with longer OS and DFS in the adjuvant treated
patients, with p-values of 0.016 and 0.02, respectively, but not in
patients not treated with adjuvant therapy (p-values of 0.49 and
0.93, respectively). This differential association between miR-21
and treatment status was supported by comparing the subgroup of
low miR-21, adjuvant treated patients vs. remaining patients. The
group of patients with low miR-21 who were treated with adjuvant
treatment had median OS and DFS of 27.7 and 16.2 months,
respectively. Remaining patients had median OS of 14.3 and DFS
of 7.0 months, with p-values of 0.002 for OS, and 0.0095 for DFS.
See also Figure 1 and Figure S3.
Cox models for overall survival and disease-free survival
Using a backward selection algorithm, a Cox model was
constructed containing parameters that were found to be jointly
associated with OS. A second model was identified for prognostic
determination of DFS (Tables 3 and 4). From multivariate analysis
among all patients, as the most significantly associated parameter
for both OS and DFS, patients with low miR-21 who were treated
with adjuvant therapy were shown to have a significantly lower
hazard ratio (HR) for death (0.443, 95%CI: 0.263–0.748; p-value,
0.002) and for recurrence (0.358, 95%CI: 0.188–0.682; p-value:
0.002) compared to all remaining patients. In contrast, in patients
not treated with adjuvant therapy, lower than median miR-21
expression was not associated with a significantly different HR for
death or recurrence of 0.880, p-values 0.76 and 0.30, respectively.
Comparison of covariates according to adjuvant treated
vs. untreated patients
Since cases were not randomized for treatment in this study, we
wanted to determine if there were significant differences in the
covariate distribution between the patients treated and not treated
with adjuvant therapy (Table S5). The only significant difference
was a lower median age in the adjuvant treated group at 61 years
(range: 45–75 years) vs. 66 years (range: 49–83 years) in the
untreated group (p-value: 0.002, Wilcoxon two-sample test). See
Table S6 for differential protein expression. Additionally, we
Table 1. Clinical characteristics of pancreatic ductal
adenocarcinoma (PDAC) patients.
Characteristic Subcategory
Korean
cohort, n
Italian
cohort, n
No. patients N/A 82 45
Age, years #64 41 24
.64 41 21
Sex Male 53 17
Female 29 28
p-AJCC stage* I 0 0
IIA 31 7
IIB 50 26
III 1 8
IV 0 4
Tumor size** ,15 mm 3 Na
15–20 mm 10 Na
.20 mm 69 Na
Lymph node negative 29 8
positive 51 37
unknown 2 0
Differentiation grade Well 6 5
Moderate 68 20
Poor 8 19
Unknown 0 1
Angiolymphatic invasion No 43 Na
Yes 39 Na
Venous invasion No 65 Na
Yes 17 Na
Vascular invasion
(venous and arterial)
No Na 31
Yes Na 14
Perineural invasion No 23 32
Yes 59 13
Adjuvant therapy Yes 52 45
No 27 0
Unknown 3 0
Abbreviations: N/A: not applicable; Na: not available.
*pAJCC pathologic tumor stage was determined according to the American
Joint Committee on Cancer (AJCC) Cancer Staging, 6th edition.
**Since there were no cases of tumor size,10 mm, tumor size was categorized
in the following 3 groups: ,15 mm, 15–20 mm and .20 mm.
doi:10.1371/journal.pone.0010630.t001
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constructed separate Cox models for patients treated with
adjuvant therapy vs. patients not treated with adjuvant therapy.
First, we did a univariate analysis in both groups (Tables S7 and
S8). Cox model analysis demonstrates that only in the subgroup of
adjuvant treated patients low miR-21 status was associated with a
significantly lower HR for death and recurrence (Table 5, Table 6,
Table 7 and Table 8). In the subgroup of not adjuvant treated
patients, positive angiolymphatic invasion and expression of miR-
34a above the median were associated with increased HR for
death and recurrence, respectively, while miR-21 did not have a
sufficiently low p-value for inclusion in the final model.
Comparison of covariates according to miR-21
expression
Distribution of clinicopathological and IHC covariates was
compared between low miR-21 and high miR-21 patients, as
reported in Table 9 and Table S9. Median age in the low miR-21
group was 63 years (range: 45–83 years), not significantly different
from the high miR-21 group, median age 64 years (range: 46–78
years), p-value: 0.94. However, there was a trend towards a more
advanced AJCC stage (IIa vs IIb) in the high miR-21 expression
group (p-value: 0.07). Similarly, there were more cases with poor
differentiation grade in the high miR-21 group, although this
group also contained more cases with well-differentiated tumors
(Table 5). We could not confirm a previously reported association
of miR-21 and TIMP3 expression [46], while we found that P-c-
Met and VEGF expression was significantly more common in
miR-21 high cases (Table S9).
As high miR-34a expression was demonstrated to be associated
with decreased DFS we have additionally compared distribution of
clinicopathological and IHC covariates between low miR-34a and
high miR-34a patients. High expression of miR-34a was strongly
associated with high expression of phospho-c-Met (p-value: 1x10E-
6). Additionally, high miR-34a expression was associated with low
expression of HGF (p-value: 0.01) as well as high expression of
VEGF (p-value: 0.01). Finally, low miR-21 expression was more
frequently observed in miR-34a low cases (p-value: 3x10E-8).
High miR-21 expression shows association with increased
distant recurrence rate
Next, we compared the rate of local vs. distant recurrence of
disease in the low vs. high expression group of miR-21. In the high
miR-21 expression group 25 out of 41 patients (61%) had
recurrent disease at a distant site which was significantly different
from the low miR-21 expression group in which only 12 out of 38
patients (32%; with 3 patients lost for follow-up) experiencing
distant recurrence (p-value: 0.013). For comparison, in the group
that received adjuvant therapy 25 out of 51 patients (49%) had
recurrent disease. This was not significantly different from the
group not treated with adjuvant therapy with 11 out of 26 patients
(42%) experienced distant recurrence (p-value: 0.63; with 5/82
patients missing due to insufficient data).
Although not statistically significant, high miR-21 expression
also showed a trend towards higher stage and positive lymph node
status (Table 5).
Validation cohort
A series of 45 resected pancreatic adenocarcinoma patients, all
treated with adjuvant gemcitabine, was used to validate the
predictive role of miR-21 expression in Caucasians. Median OS
and DFS were 20.4 and 18.7 months, respectively. See Table 1 for
clinicopathological parameters (Italian cohort). MiR-21 expression
was detectable in all specimens. Univariate analysis showed a
Table 2. Tissue microarray immunohistochemistry results
Korean pancreatic adenocarcinoma patients.
Proteins Expression Total, n (%)
Amphiregulin Negative 27 (36%)
Positive 49 (64%)
Epiregulin Negative 22 (31%)
Positive 49 (69%)
Ron b Negative 18 (24%)
Positive 57 (76%)
HGF Negative 29 (38%)
Positive 47 (62%)
CXCR3 Negative 64 (85%)
Positive 11 (15%)
CXCR4 Negative 11 (15%)
Positive 63 (85%)
E-cadherin Negative 1 (1%)
Positive 74 (99%)
RRM1 Negative 62 (83%)
Positive 13 (17%)
ERCC1 Negative 46 (64%)
Positive 26 (36%)
ERCC1 (H-score) Negative 18 (25%)
Positive 54 (75%)
TS Negative 71 (95%)
Positive 4 (5%)
EGFR Negative 59 (78%)
Positive 17 (22%)
IGF-1R Negative 57 (76%)
Positive 18 (24%)
Neurophilin Negative 27 (35%)
Positive 50 (65%)
VEGF Negative 25 (33%)
Positive 50 (67%)
c-Met Negative 56 (77%)
Positive 17 (23%)
phosporylated-c-Met Negative 40 (55%)
Positive 33 (45%)
MMP2 Negative 26 (35%)
Positive 49 (65%)
MMP7 Negative 21 (28%)
Positive 54 (72%)
MMP9 Negative 7 (9%)
Positive 70 (91%)
TIMP3 Negative 28 (37%)
Positive 47 (63%)
Abbreviations: Chemokine (C-X-C motif) receptor 3 (CXCR3), chemokine (C-X-C
motif) receptor 4 (CXCR4), epidermal growth factor receptor (EGFR), excision
repair cross-complementation group 1 (ERCC1), hepatocyte growth factor
(HGF), insulin-like growth factor 1 receptor beta (IGF-1R), matrix
metalloproteinase-2 (MMP2), matrix metalloproteinase-7 (MMP7), matrix
metalloproteinase-9 (MMP9), ribonucleotide reductase subunit M1 (RRM1),
thymidylate synthase (TS), tissue inhibitor of metalloproteinase-3 (TIMP3) and
vascular endothelial growth factor (VEGF).
doi:10.1371/journal.pone.0010630.t002
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trend towards significant association between poor tumor
differentiation and shorter OS (p-value: 0.07), while the occur-
rence of neural infiltration was marginally associated with
significantly shorter DFS (p-value: 0.047), but not OS (p-value:
0.90), as reported in Table S10. Age, gender, stage, lymph node,
and vascular infiltration were not associated with outcome.
Patients with high miR-21 expression had a significantly shorter
OS, i.e. median 15.6 compared to 24.4 months in patients with
miR-21 expression level inferior to median (p-value: 0.006). The
median DFS of patients with high miR-21 expression was 14.0
months, compared to 23.8 months in patients with the low miR-21
expression (p-value: 0.0042). See Figure 2 for Kaplan-Meier
curves. Cox models were constructed which confirmed the
association of miR-21 expression status and survival duration,
with high miR-21 expression, as the only remaining factor,
associated with an increased HR for death at 3.538 (95%CI:
1.415–8.849; p-value: 0.007) and recurrence at 4.008 (95%CI:
1.385–11.595; p-value: 0.01). Pooled analysis of the two cohorts
confirmed the significant predictive importance of miR-21
expression status, as reported in Figures S4 and S5.
MiR-21 and antiproliferative effects of 5-FU in PDAC cells
Expression of miR-21 was detectable in all PDAC cell lines,
ranging from 4.5 in PL45 cells to 1.5 a.u. in the BxPC-3 cells
(Figure 3A). A dose-dependent inhibition of cell growth was observed
after both 5-FU, and gemcitabine plus radiotherapy treatment, as
Figure 1. Survival analysis of adjuvant treated and not adjuvant treated patients. Overall survival according to miR-21 status in (A) not
adjuvant treated patients and (B) adjuvant treated patients. Disease-free survival according to miR-21 status in (C) not adjuvant treated patients and
(D) adjuvant treated patients. Cens.: censored.
doi:10.1371/journal.pone.0010630.g001
Table 3. Multivariate analysis of all patients: overall survival.
Comparison
Hazard ratio
for death 95% CI p-value
(Adjuvant treated,
miR-21 negative) vs. rest
0.443 0.263–0.748 0.0023
Angiolymphatic invasion:
positive vs. negative
1.769 1.091–2.868 0.0208
doi:10.1371/journal.pone.0010630.t003
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shown in Figure 3B-C. In particular, 5-FU treatment resulted in a
modest inhibition of cell growth in PANC-1 and PL45 cells, with
IC50s of 138.4623.4 mM and 174.2631.1 mM, respectively. Among
the studied cell lines, BxPC3 and HPAF-II were the most sensitive to
gemcitabine and 5-FU, respectively, while PL45 was the most
resistant to both 5-FU and gemcitabine plus radiotherapy.
Although the small number of cell lines used in this study precluded
the assessment of the predictive value of miR-21 expression as a
validated determinant of chemosensitivity, the cell lines with low
miR-21 expression (BxPC-3 and HPAF-II) had a significantly lower
IC50 than the cell lines with high miR-21 expression (PANC-1 and
PL45), p-value: 0.0079 (Mann-Whitney test).
To further explore this potential association, relatively sensitive
(HPAF-II), and resistant (PL45) cells were transfected with a miR-21
specific antisense inhibitor. Transfection efficiency was evaluated by
analysis of fluorescent microscope images of cells 24 hours post
transfection with a specific FAM-dye precursor or antisense anti-mir
oligonucleotides (Figure 3D, picture). There was at least 80%
transfection efficiency, for both cell lines, with .70% cell viability.
Furthermore, we assessed miR-21 expression by quantitative Real-
Time PCR in the transfected cells, showing a 3 and 2.5-fold decrease
of miR-21 expression in PL45 and HPAF-II cells, respectively
(Figure 3D, bar graph). In order to evaluate the modulation of 5-FU
anti-proliferative effects, we studied whether co-treatment of anti-
miR-21 and 5-FU in PL45 cells would result in increased sensitivity to
5-FU. For this experiment, the selected cell lines were pretreated with
anti-miR-21 for 24 hours, followed by 5-FU for an additional
48 hours. As shown in Figure 3E the transfection with anti-miR-21
resulted in an increased activity of 5-FU, with a reduction of 5-FU
IC50 values from 174.2631.1 to 62.5615.9 mM in PL45 cells and
from 30.963.4 to 11.362.1 mM in HPAF-II cells.
Discussion
In the present study 27 biological (20 proteins and 7
microRNAs) and 9 clinicopathological factors were jointly assessed
in order to determine biomarkers for clinical outcome in patients
treated or not treated with adjuvant therapy following surgical
resection of PDAC. Of these 36 covariates analyzed, miR-21
expression was the only factor consistently associated with OS and
DFS in all Cox model analyses when evaluated according to
treatment status in an initial series of 82 Korean patients. Adjuvant
treated patients with low miR-21 expression were shown to have a
favorable outcome compared to patients with high miR-21
expression.
Our findings are in agreement with a previous study which
showed that miR-21 overexpression, as determined by in situ
hybridization, was predictive of shorter survival only in PDAC
node-negative patients. However, the subset of node-negative
patients was small (n = 17) and no data were available on patient
treatment or other clinicopathological characteristics [28]. Our
study extended the analysis to patients receiving adjuvant therapy
and compared these patients with not treated patients. Further-
more, we evaluated a wide variety of clinicopathological and
biological factors suggesting that miR-21 is the most predictive
marker for survival of any of these factors in adjuvant-treated
patients.
According to the final results of the recently reported CONKO-
001 and ESPAC-3 trials, adjuvant chemotherapy increased DFS
and OS duration [47–49]. Still, the most effective adjuvant
regimen and the role of radiotherapy remain unclear, and
identification of predictive factors for survival is critical to
maximize therapeutic efficacy in selected patients.
The expanding knowledge of the molecular pathogenesis of
cancer is providing new targets for disease characterization, which
might also be used as new markers to select patients for better
clinical management. In particular, there is a growing number of
studies on miRNAs, which are classified as oncogenes or tumor-
suppressor genes and have a pivotal role in progression and
prognosis of different tumors [16]. A specific miRNA can affect
simultaneously the expression of proteins involved in multiple
cellular pathways, potentially serving as better therapeutic target
or biomarker for clinical outcome than single proteins. Further-
Table 4. Multivariate analysis of all patients: disease-free survival.
Comparison Hazard ratio for recurrence 95% CI p-value
(Adjuvant treated, miR-21 negative) vs. rest 0.358 0.188–0.682 0.0018
Angiolymphatic invasion: positive vs. negative 1.923 1.106–3.344 0.0206
Amphiregulin status: positive vs. negative 0.512 0.276–0.951 0.0342
(Not adjuvant treated, miR-34a positive) vs. rest 7.375 2.315–23.491 0.0007
Adjuvant treated vs. rest 0.419 0.196–0.894 0.0244
(Adjuvant treated, pN negative) vs. rest 0.310 0.152–0.632 0.0013
doi:10.1371/journal.pone.0010630.t004
Table 5. Multivariate analysis of adjuvant treated patients:
overall survival.
Comparison
Hazard ratio
for death 95% CI p-value
(Adjuvant treated,
miR-21 negative) vs. rest
0.316 0.166–0.600 0.0004
CXCR3 status: positive vs.
negative
4.177 1.775–9.831 0.0011
AJCC stage: IIB vs. IIA 2.092 1.078–4.058 0.0290
doi:10.1371/journal.pone.0010630.t005
Table 6. Multivariate analysis of adjuvant treated patients:
disease-free.
Comparison
Hazard ratio
for recurrence 95% CI p-value
(Adjuvant treated,
miR-21 negative) vs. rest
0.521 0.280–0.967 0.0387
pN status: positive vs. negative 1.968 1.026–3.775 0.0416
doi:10.1371/journal.pone.0010630.t006
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more, technological advances have made it possible to reliably
determine miRNA expression using FFPE tissues, and previous
studies showed that miRNA expression in FFPE correlated with
expression in matched fresh/frozen tissues [50–53]. Accordingly,
in the present study miRNAs were successfully extracted and
evaluated from both FFPE and frozen laser microdissected
specimens.
The miRNAs currently analyzed were selected from the
comparison of miRNA expression patterns in normal and tumoral
pancreatic tissues [29], as well as from the results of several
preclinical studies, suggesting their role in tumor progression and
sensitivity [13,31,33,34]. In particular, the transfection with miR-
21 precursor reduced gemcitabine sensitivity of PANC-1 cells [33],
while antisense inhibition of miR-21 led to cell cycle arrest,
induced apoptosis and sensitized the effects of gemcitabine in
HS766T cells [54], suggesting a key role of miR-21 in modulating
the response to this specific drug in PDAC cells. However, miR-21
expression was correlated with resistance to several anticancer
agents in different models [55–58]. The studies of Meng et al.
showed a correlation of miR-21 expression and gemcitabine-
induced apoptosis and modulation of PTEN and associated
pathways, thus affecting phenotypic characteristics such as cell
growth, migration, and invasion in cholangiocarcinoma and
hepatocellular carcinoma in vitro and in vivo [55,56]. More recently,
Li et al. found that the repression of miR-21 expression sensitizes
glioblastoma cells to VM-26 treatment via leucine rich repeat
interacting protein (LRRFIP1)-mediated inhibition of NF-kB
signaling, a principal mechanism of tumor chemoresistance [18].
Moreover, combined suppression of miR-21 with S-TRAIL in
glioma cells leads to a synergistic cytotoxicity and increased
caspase activity, which was associated with reduction of tumor
growth both in vitro and in vivo [59]. Inhibition of miR-21
expression has also been shown to sensitize MCF-7 cells to
topotecan by inducing an increased apoptotic response, partly
caused by downregulation of the anti-apoptotic protein Bcl-2 [60].
The patients of the Korean cohort enrolled in this study were
treated with various gemcitabine or 5-FU containing adjuvant
regimens, suggesting that miR-21 expression can affect outcome of
both gemcitabine and 5-FU-based treatment. Accordingly, the
higher expression of miR-21 was detected in PDAC cells with the
higher IC50 values for 5-FU, while miR-21 suppression with a
specific anti-miR significantly increased the antiproliferative effects
of 5-FU. To our knowledge, this is the first study showing a
correlation between miR-21 expression and 5-FU activity and
these data might explain the results of a previous clinical study,
showing that high miR-21 expression was associated with poor
outcome in colon cancer patients treated with adjuvant 5-FU-
based chemotherapy [61].
In the present study, high miR-21 expression was also associated
with an increased distant recurrence rate, suggesting a role in the
metastatic behavior of pancreatic adenocarcinoma. Accordingly,
high miR-21 expression levels correlated with increased prolifer-
ation and occurrence of liver metastasis in previous studies in
PDAC cells [33] and in pancreatic endocrine tumors [62].
However, as shown by the analysis in the subgroup of patients
not treated with adjuvant therapy, low miR-21 expression on its
own was not associated with prolonged OS or DFS, negating its
role as a purely prognostic factor.
Several other parameters were associated with OS or DFS
according to adjuvant treatment status, including angiolymphatic
invasion, CXCR3 and miR-34a. However, in the Cox model
analyses, none of these markers were found to be associated with
both OS and DFS in the adjuvant treated patient subgroup and/
or the untreated group. Positive angiolymphatic invasion, as
determined on the surgical specimen, was associated with worse
OS and DFS in the total population and with worse OS in the
patient subgroup not treated with adjuvant therapy, as reported
previously [63]. However, in the treated subgroup, angiolymphatic
invasion was not a significant factor at the univariate analysis. In
adjuvant treated patients positive CXCR3 expression and
advanced stage were also associated with worse treatment outcome
in terms of OS. Recent studies suggested that the CX3CR1
receptor may be involved in PDAC neurotropism and is a relevant
and independent risk factor to predict an early local tumor relapse
in resected patients, but further studies are needed to unravel the
complex network of chemokines and their receptors in the
pancreatic cancer microenvironment [64]. High miR-34a expres-
sion was associated with decreased DFS at the multivariate
analysis in the not adjuvant treated patients. Furthermore, we
found a significant correlation between high miR-34a expression
and high VEGF and p-c-Met levels, which have been correlated
with increased microvessel density, tumor metastatic potential,
local disease progression and chemoresistance in a variety of
malignancies, including PDAC [65,66]. However, high expression
levels of VEGF and p-c-Met were also associated with high
expression of miR-21 and the comparison between miR-21 (low
vs. high) with miR-34a (low vs. high) expression showed a
significant association, likely explaining why both these two
miRNAs did not typically end up in the same Cox model.
Although miR-21 expression was shown to be the single most
important predictive factor from 36 covariates tested, it is crucial
to validate findings by follow-up prospective studies in indepen-
dent cohorts with controlled treatment regimens. In the present
study miR-21 was confirmed to be a biomarker for treatment
outcome in an independent patient cohort. This second cohort
was added only after the end of the first study, and we are aware of
the limitations of our comparison. Interestingly, these patients had
different ethnicity (Caucasian vs. Asian), specimens (frozen tissues
vs. FFPE), treatment (gemcitabine + radiotherapy vs. gemcitabine
or fluoropyrimidines) and endogenous controls in the PCR
reactions (RNU43 vs. U66), suggesting that miR-21 might be
used as effective biomarker for different populations/treatments,
and when different types of specimens/PCR reagents are
available.
Concluding, low miR-21 expression was associated with
increased survival following adjuvant treatment in two
Table 7. Multivariate analysis of patients not treated with
adjuvant therapy: overall survival.
Comparison
Hazard ratio
for death 95% CI p-value
Angiolymphatic invasion:
positive vs. negative
3.452 1.306–9.125 0.0125
doi:10.1371/journal.pone.0010630.t007
Table 8. Multivariate analysis of patients not treated with
adjuvant therapy: disease-free survival.
Comparison
Hazard ratio for
recurrence 95% CI p-value
miR-34a status: positive
vs. negative
4.435 1.604–12.263 0.0041
doi:10.1371/journal.pone.0010630.t008
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independent cohorts of PDAC cases, and anti-miR-21
increased anticancer drug activity in vitro. These data provide
evidence that miR-21 may allow stratification for adjuvant
therapy, thus offering a potential new biomarker for treatment
selection and personalized therapy. Furthers studies are
warranted.
Table 9. Korean cohort: association of miR-21 expression with clinicopathological covariates.
Characteristic Subcategory Low miR-21, n (%) High miR-21, n (%) Total, n (%) p-value
Sex Male 26 (63%) 27 (66%) 53 (65%) 1.00
Female 15 (37%) 14 (34%) 29 (35%)
Age, years ,55 6 (15%) 4 (10%) 10 (12%) 0.65
55-64 17 (41%) 21 (51%) 38 (46%)
.64 18 (44%) 16 (39%) 34 (41%)
p-AJCC stage* IIa 20 (49%) 11 (28%) 31 (38%) 0.07
IIb 21 (51%) 29 (73%) 50 (62%)
Tumor size** ,15 mm 2 (5%) 1 (2%) 3 (4%) 1.00
15–20 mm 5 (12%) 5 (12%) 10 (12%)
.20 mm 34 (83%) 35 (85%) 69 (84%)
pN stage 0 18 (44%) 11 (27% 29 (35%) 0.16
1 22 (54%) 29 (71%) 51 (62%)
unknown 1 (2%) 1 (2%) 2 (2%)
Differentiation grade Well 1 (2%) 5 (12%) 6 (7%) 0.02
Moderate 37 (90%) 29 (71%) 66 (80%)
Poor/undifferentiated 1 (2%) 7 (17%) 8 (10%)
unknown 2 (5%) 0 (0%) 2 (2%)
Angiolymphatic invasion No 24 (59%) 19 (46%) 43 (52%) 0.38
Yes 17 (41%) 22 (54%) 39 (48%)
Venous invasion No 31 (76%) 34 (83%) 65 (79%) 0.59
Yes 10 (24%) 7 (17%) 17 (21%)
Perineural invasion No 14 (34%) 9 (22%) 23 (28%) 0.33
Yes 27 (66%) 32 (78%) 59 (72%)
*pAJCC pathologic tumor stage was determined according to the American Joint Committee on Cancer (AJCC) Cancer Staging, 6th edition.
**Since there were no cases of tumor size,10 mm, tumor size was categorized in the following 3 groups: ,15 mm, 15–20 mm and .20 mm.
doi:10.1371/journal.pone.0010630.t009
Figure 2. Survival analysis in adjuvant treated patients from the Italian cohort. (A) Overall survival according to miR-21 status and (B)
disease-free survival status according to miR-21 status. Cens.: censored.
doi:10.1371/journal.pone.0010630.g002
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Figure 3. In vitro studies validating the role of miR-21 in PDAC chemosensitivity. (A) MiR-21 expression in 5 PDAC cell lines. Expression was
determined by quantitative PCR, using the delta Ct method with RNU-43 as reference and the values are in a.u.. (B–C) Representative curves of
growth inhibitory effects of 5-FU (B) and gemcitabine plus radiotherapy (C), 48-hour drug exposure. (D). Cells were seeded at 104/well and the anti-
proliferative effects were evaluated using the SRB assay, as described in the methods. The mean IC50 values for 5-FU (48 h continuous exposure) were
as follows: 36.3 mM (BxPC-3), 30.9 mM (HPAF-II), 138.4 mM (PANC-1) and 174.2 mM (PL45); while the IC50 values for gemcitabine (in cells pre-treated
with 100 cGray) were 2.1 nM (BxPC-3), 3.4 nM (HPAF-II), 10.2 nM (PANC-1) and 11.4 nM (PL45). (D) MiR-21 expression in HPAF-II and PL45 cells
transfected with negative controls or with anti-miR-21 oligos. Transfection efficiency was evaluated by fluorescence microscopy as shown in the
pictures in the upper panel, original magnification, x40 (E) Modulation of 5-FU antiproliferative effects in PL45 cells transfected with anti-miR-21 in
comparison with control transfected cells. Columns, mean values obtained from three independent experiments; bars, SE, dashed lines, concentrations
corresponding to 50% inhibition of cell growth with respect to control, i.e. IC50 values.
doi:10.1371/journal.pone.0010630.g003
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Supporting Information
Figure S1 Survival curves of Korean pancreatic adenocarcino-
ma patients. (A) overall survival and (B) disease-free survival, in
total study population. (C) overall survival, by pAJCC stage. (D)
overall survival, by treatment status. Cens.: censored.
Found at: doi:10.1371/journal.pone.0010630.s001 (5.08 MB TIF)
Figure S2 Representative images of two pancreatic adenocarci-
noma cases from the Korean cohort stained by immunohisto-
chemistry for phosphorylated c-Met (p-c-Met), according to the
methodology and scoring algorithm as described in the Methods
section. A, example of a case with a positive staining pattern for
phosphorylated c-Met; B, example of a case with a negative
staining pattern for phosphorylated c-Met.
Found at: doi:10.1371/journal.pone.0010630.s002 (3.82 MB TIF)
Figure S3 Survival curves according to miR-21 expression and
treatment status (A) overall survival and (B) progression-free
survival, according to miR-21 status combined with adjuvant
treatment status. (C) overall survival and (D) disease-free survival,
comparing low miR-21 patients who received adjuvant chemo-
therapy to rest. Abbreviations used: ‘‘miR-21 high/adj’’: high
miR-21, having received adjuvant treatment; ‘‘miR-21 low/adj’’:
low miR-21 expression, having received adjuvant treatment;
‘‘miR-21 high/no adj’’: high miR-21, no adjuvant treatment;
‘‘miR-21 low/no adj’’: low miR-21, no adjuvant treatment. Cens.:
censored.
Found at: doi:10.1371/journal.pone.0010630.s003 (5.10 MB TIF)
Figure S4 Pooled analysis Korean and Italian cohorts: disease-
free survival curves according to miR-21 expression and treatment
status.
Found at: doi:10.1371/journal.pone.0010630.s004 (0.19 MB TIF)
Figure S5 Pooled analysis Korean and Italian cohorts: overall
survival curves according to miR-21 expression and treatment
status.
Found at: doi:10.1371/journal.pone.0010630.s005 (0.19 MB TIF)
Table S1 Clinicopathological and biological factors analyzed.
Found at: doi:10.1371/journal.pone.0010630.s006 (0.05 MB
DOC)
Table S2 Adjuvant therapy regimens.
Found at: doi:10.1371/journal.pone.0010630.s007 (0.05 MB
DOC)
Table S3 Antibodies used for immunohistochemistry.
Found at: doi:10.1371/journal.pone.0010630.s008 (0.04 MB
DOC)
Table S4 Univariate analysis Korean cohort.
Found at: doi:10.1371/journal.pone.0010630.s009 (0.07 MB
DOC)
Table S5 Korean cohort: clinicopathological covariates accord-
ing to treatment status.
Found at: doi:10.1371/journal.pone.0010630.s010 (0.07 MB
DOC)
Table S6 Korean cohort: immunohistochemistry covariates
according to treatment status.
Found at: doi:10.1371/journal.pone.0010630.s011 (0.10 MB
DOC)
Table S7 Korean cohort: univariate analysis in adjuvant treated
patients.
Found at: doi:10.1371/journal.pone.0010630.s012 (0.04 MB
DOC)
Table S8 Korean cohort: univariate analysis in not adjuvant
treated patients Korean cohort.
Found at: doi:10.1371/journal.pone.0010630.s013 (0.04 MB
DOC)
Table S9 Korean cohort: association miR-21 and immunohis-
tochemistry covariates.
Found at: doi:10.1371/journal.pone.0010630.s014 (0.09 MB
DOC)
Table S10 Italian cohort: univariate analysis in adjuvant treated
patients.
Found at: doi:10.1371/journal.pone.0010630.s015 (0.04 MB
DOC)
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